Fund of Funds
Leveraging our experience as direct VC investors we are able to co-invest in
highly competitive deals and carry out complex secondary transactions.
Aurora is Axon’s fund-of-funds arm, investing in top-performing GPs in the ICT and life science spaces. Our aim is to provide our LPs with exposure to the VC market through a professionally managed and diversified portfolio. We complement our primary investments in funds with secondary transaction in funds and co-investments in portfolio winners.
Built on proprietary research
Axon’s experience and positioning in the VC market allow us differentiate our strategy from that of traditional FoF managers. We follow a bottom-up approach, providing access to the best market-validated GPs and emerging managers. We invest globally, with a focus on the Pan-European region (EU, UK, Israel and the Nordics).
Our approach is built on proprietary research, especially across the unique aspects of the Pan-European ecosystem and the life science sector, a fundamental part of our allocation. We have observed tangible advantages in this approach, which allows us to create a portfolio that provides both superior risk-adjusted returns and liquidity for our LPs.
Why Axon Fund of Funds?
- Our specialised tech-VC team has privileged access to top global VCs, with a unique skill set to select best GPs across different strategies and geographies.
- We leverage our experience as direct VC investors to access both the best established and emerging managers, as well as to co-invest in highly competitive deals and carry out complex secondary transactions.
- A disciplined portfolio construction with an optimised cash flow model provides superior risk-adjusted returns.
News and insights
Europe’s future: the promise of green hydrogenRead more: Europe’s future: the promise of green hydrogen
Discipline or luck, that is the question.Read more: Discipline or luck, that is the question.
Unlocking the Power of Life Sciences: A Compelling Investment OpportunityRead more: Unlocking the Power of Life Sciences: A Compelling Investment Opportunity